Cancer gene therapy – state-of-the-art

A number of gene therapy clinical trials are being carried out the world over. Gene therapy is being applied in (I) cancer diseases, involving the largest number of patients, (II) monogenic diseases, (III) infectious diseases, (IV) vascular diseases, (V) autoimmune diseases and others. In the last decade, several strategies of cancer gene therapy have emerged due to a rapid development of gene delivery systems, both viral (recombinant retroviruses, adenoviruses, AAVs, herpes viruses) and nonviral (liposomes, gene guns, electroporation). To date four main strategies of cancer gene therapy have been evaluated in clinical trials: (I) immunogene therapy, (II) suicide gene therapy, (III) antiangiogenic gene therapy, (IV) and administration of tumour suppressor genes.These strategies mostly involve: malignant melanoma, prostate cancer, renal cell cancer, colon cancer, breast and ovarian cancers, lung cancers, neoplastic diseases of the blood and brain tumours.At the Department of Cancer Immunology at the GreatPoland Cancer Center Gene Modified Tumour Vaccine has been tested in malignant melanoma patients for more than six years. Due to encouraging results from phase I and II of clinical trials a phase III was designed and will be started in 2003.     

Cancer Res:肿瘤形成新机制

正在一项新的研究中,来自美国罗格斯大学和哥伦比亚大学的研究人员鉴定出一个基因在肺部结节性硬化症的肿瘤形成中起着关键性的作用。这一发现可能为人们提供一种潜在的新药物靶标,也可能改变人们对肿瘤形成的常规认识。结节性硬化症(tuberous sclerosis complex,TSC)是一种罕见的疾病,在这种疾病中,良性肿瘤在包括肺部、大脑、肾脏、眼睛和心脏在内的重要     

Cancer Cell:癌症治疗新思路

<正>近年来,热门的癌症化个体化治疗方案往往聚焦于,与不同类型的癌症相关联的,特异性的基因突变。不同于以往的癌症作用靶点,近日,来自Saint Louis大学的研究人员们首次发现,一种靶向Warburg效应的药物,可以从根源上阻断癌症的能量来源,从而使癌症细胞停止生长。这项研究结果最近发表于Cancer Cell杂志上。我们知道,所有的生物均有利用能量的能力,即代谢。癌症细胞大大地加快了代谢过程,使突变的细胞疯狂地生长。早在20世纪初,科学家们     

Cancer: Bad luck or punishment?

Contrasting opinions on the role of extrinsic and intrinsic factors in cancer etiology (Tomasetti, C., and Vogelstein, B. (2015) Science, 347, 78-81; Wu, S., et al. (2016) Nature, 529, 43-47) variously define priorities in the war on cancer. The correlation between the lifetime risk of several types of cancer and the total number of divisions of normal selfrenewing cells revealed by the authors has given them grounds to put forward the “bad luck” hypothesis. It assumes that ~70% of cancer variability is attributed to random errors arising during DNA replication in normal, noncancerous stem cells, i.e. to internal factors, which is impossible either to expect or to prevent. This assumption caused many critical responses that emphasize, on the contrary, the defining role of extrinsic factors in cancer etiology. The analysis of epidemio-logical and genetic data presented in this work testifies in favor of the “bad luck” hypothesis.     

Cancer immunotherapy: simply cell biology?

There is a clear need for improved cancer therapy and survival rates. Effective immunotherapy would be the treatment modality of choice from several viewpoints, and dendritic cell (DC)-based immunotherapy is emerging as the most promising approach to cancer immunotherapy. However, the plethora of approaches to DC-based cancer therapy now threatens to impede the development of an effective immunotherapy regime, as competing egos and commercial interests masquerade as scientific rigour. Here, I argue that the current controversies regarding the numerous approaches reflect the paucity of our immunological understanding, and present a simple cell biological analysis that defines the rationale for the development of effective cancer immunotherapy.     

Does Cancer Solve an Optimization Problem?

Many cancers are characterized by a high degree of aneuploidy, which isbelieved to be a result of chromosomal instability (CIN). The precise role of CIN incancer is still the matter of a heated debate. We present a quantitative framework forexamining the selection pressures acting on populations of cells and weigh the \pluses"and \minuses" of CIN from the point of view of a sel¯sh cell. We calculate the optimalrate of chromosome loss assuming that cancer is initiated by inactivation of a tumorsuppressor gene followed by a clonal expansion. The resulting rate, p* ~ ¼ 10^-2 per celldivision per chromosome, is similar to that obtained experimentally by Lengauer et al(1997). Our analysis further suggests that CIN does not arise simply because it allowsa faster accumulation of carcinogenic mutations. Instead, CIN must arise because ofalternative reasons, such as environmental factors, epigenetic events, or as a directconsequence of a tumor suppressor gene inactivation. The increased variability aloneis not a su±cient explanation for the presence of CIN in the majority of cancers.     

A special issue on ＇Cancer＇

Cancer is a set of diseases characterized by uncontrolled or inappropriate cell growth, which is strongly associated with defects in signal-transduction proteins. Understanding the molecular details of major signaling pathways is critical for developing therapeutic strategies against cancers. In this special issue, we have invited several prominent experts in the field of cancer research to summarize the recent advances in this field. The articles in this special issue can be grouped into four major topics： （i） the molecules involved in cancer signaling pathway （Feng ZH, Hu WW, Liu BL, and Wang ZH）, （ii） metabolic reprogramming and hypoxia in cancer （Lei QY and Zhang HF）, （iii） noncoding RNA and anticancer drugs （Huang X and Xi YG）, and （iv） immuno- modulatory drugs （Chang XB）.     

The Impact of Genomic Prof ling for Novel Cancer Therapy–Recent Progress in Non-Small Cell Lung Cancer

There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003.Through pains-taking analyses of genomic profiles in cancer patients,a number of targetable gene alterations have been discovered,with some leading to novel therapies,such as activating mutations of EGFR,BRAF and ALK gene fusions.As a result,clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers,such as lung adenocarcinomas and melanomas.In this review,we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer(NSCLC)as an example.We also discuss possible future implications of cancer genome analyses.     

γ-H2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics,Prediction and Recurrence

Current advances in cancer biology have identified major pathways involved in tumorigenesis. The association of DNA damage with premalignant stages of tumor progression, genome instability and further oncogenic transformation opens the possibility of using common DNA damage markers for early cancer detection, prediction, prognosis, therapeutics and possibly for cancer prevention. Perhaps the most sensitive DNA damage marker is γ-H2AX formation in the chromatin flanking the free DNA double-stranded ends in double-strand breaks (DSBs) and eroded telomeres, both present during oncogenic transformation. Our group and others found elevated endogenous levels of γ-H2AX in various human cancer cell lines, premalignant lesions and solid tumors. These data suggest that increased DNA damage is a general characteristic of cancer development. γ-H2AX-based assay can be applied to human biopsies, aspirates and, possibly, to mononuclear cells of the peripheral blood. We propose that detection of γ-H2AX could benefit for the early cancer screening and to ascertain the efficiency of clinical treatment involving chemo- and radiotherapeutic protocols.     

What Can Ecology Teach Us About Cancer?

In 2008, Pienta et al. (Transl Oncol. 2008;1:158-164) introduced the term ecological therapy for cancer treatment and, in particular, emphasized that destruction of the tumor microenvironment would be more effective than just killing the cells that inhabit it. Proposed here is an expansion on the idea of ecological therapy of cancer, incorporating 1) literature on species invasion, i.e., a right cancerous clone needs to be at the right place at the right time to actually invade its environment, and 2) the literature on niche construction, that is, the idea that once a tumor is formed, cancer cells they modify their microenvironment (niche construction) by changing pH through glycolysis, secreting growth factors and recruiting tumor-associated macrophages to promote cell growth, activating fibroblasts, evading predation from immune system, making the cancer that much more difficult to eradicate. Paleontological literature suggests that the largestmass extinctions occurred when environmental stress that would weaken the population was coupled with some pulse destructive event that caused extensive mortality. To have the same effect on cells in the tumor, rather than, or at least in addition to, killing the cells, one would also need to target the niche that they created for themselves.     

Cancer: A matter of life cycle?

In the last decade, the concept of "cancer stem cells" has emerged, recognised by the fact that only a small fraction of tumour cells appears to retain the stem cell properties of self-renewal and unlimited proliferation. At the same time, it is well known that cancer is an age-related disease developing at the limit of proliferating cell senescence. The apparent need to link senescence and the capacity for self-renewal has lead some authors to suggest that cancers develop from amongst senescing stem cells. However, an alternative solution has recently been proffered by Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R [Neosis: a novel type of cell division in cancer. Cancer Biol Ther 2004;3:207-18], who suggest that stemness may be a transient, cyclic property afforded by de-polyploidisation of senescing cells which have undergone polyploidisation. In this mini-review, we attempt to reconcile both of these views by the idea that cycling polyploidy intermitting senescence and rejuvenation may be features of a life cycle analogous to the life cycles of certain unicellular organisms. Furthermore, we suggest that mitotic catastrophe may represent a mechanism through which the cell can switch from the usual mitotic cell-cycle to this evolutionarily conserved life cycle. Intriguingly, some most recent data suggest that cell senescence may be reversible and that stem cells are tolerant to polyploidy caused by genotoxic stress.